Emisphere Technologies, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues for the first quarter ended March 31, 2015 were $6,000, compared to $0 revenue recognized in the first quarter ended March 31, 2014. The increase was primarily due to the commercialization of Eligen B12 which was launched in March 2015.

The company reported a net loss of $33 million, or $0.54 per basic and diluted share, compared to net loss of $3.4 million, or $0.06 per basic and diluted share, for the same prior year period. Operating loss was $4.668 million against $2.345 million a year ago. Loss before income tax benefit was $32.968 million against $5.042 million a year ago.